当前位置： SCI文献检索 > ANNALS OF HEMATOLOGY期刊下所有文献 > Modified ProMACE-MOPP hybrid regimen with moderate-dose methotrexate for patients with primary CNS lymphoma.

Modified ProMACE-MOPP hybrid regimen with moderate-dose methotrexate for patients with primary CNS lymphoma.

Abstract：

:The object of this study was to assess the estimation of 2- and 5-year overall survival and tumor response and the frequency and severity of treatment morbidity with a modified ProMACE-MOPP hybrid protocol in patients with primary CNS lymphoma (PCNSL). Thirty-two immunocompetent patients were treated with a regimen of pirarubicin, cyclophosphamide, etoposide, vincristine, and methotrexate (500 mg/m(2)) administered in 21-day cycles. Intraventricular 10 mg of methotrexate was given for eight cycles once a week. Patients received 20 Gy of whole brain radiotherapy after three cycles of chemotherapy. A single cycle of chemotherapy was repeated every 4 months for 2 years. Older patients (aged >60) received a reduced dose of chemotherapeutic agents. Eighteen patients were followed up with neuroimaging and neuropsychological assessments for evidence of CNS toxicity. Sixteen patients completed the regimen as planned. The response rate was 87.5% after the initial chemoradiotherapy. The cumulative survival and progression-free survival rates at 5 years were 56 and 31%, respectively. The median survival time was 68 months. The median progression-free survival time was 39 months. Toxicity included grade 3 or 4 leukopenia in 33% of the cycles administered. There were eight grade 3 or 4 pulmonary toxicities. There were three deaths during chemotherapy: one as a result of sepsis and two of pneumonitis. Three patients (25%) experienced delayed neurologic toxicity while on the complete regimen. Maintaining the dose of methotrexate while adding chemotherapeutic agents improved disease control and overall survival in patients with PCNSL, but early toxicity and delayed neurotoxicity are still a risk of this approach.

journal_name

Ann Hematol

journal_title

Annals of hematology

authors

Yamanaka R,Morii K,Shinbo Y,Takeuchi S,Tamura T,Hondoh H,Takahashi H,Onda K,Takahashi H,Tanaka R

doi

10.1007/s00277-005-1005-9

subject

Has Abstract

pub_date

2005-07-01 00:00:00

pages

447-55

issue

7

eissn

0939-5555

issn

1432-0584

journal_volume

84

pub_type

杂志文章,多中心研究

相关文献

ANNALS OF HEMATOLOGY文献大全
  • Chemotherapy-induced mesenchymal stem cell damage in patients with hematological malignancy.

    abstract：:Hematopoietic recovery after high-dose chemotherapy (HDC) in the treatment of hematological diseases may be slow and/or incomplete. This is generally attributed to progressive hematopoietic stem cell failure, although defective hematopoiesis may be in part due to poor stromal function. Chemotherapy is known to damage ...

    journal_title：Annals of hematology

    pub_type： 临床试验,杂志文章

    doi：10.1007/s00277-009-0896-2

    authors： Kemp K,Morse R,Wexler S,Cox C,Mallam E,Hows J,Donaldson C

    更新日期：2010-07-01 00:00:00

  • Global coagulation in myeloproliferative neoplasms.

    abstract：:In spite of their recognized risk of thrombosis, patients with myeloproliferative neoplasms (MPN) show little or no abnormalities of traditional coagulation tests, perhaps because these are unable to represent the balance between pro- and anticoagulants nor the effect of platelets and blood cells. We investigated whet...

    journal_title：Annals of hematology

    pub_type： 杂志文章

    doi：10.1007/s00277-013-1834-x

    authors： Tripodi A,Chantarangkul V,Gianniello F,Clerici M,Lemma L,Padovan L,Gatti L,Mannucci PM,Peyvandi F

    更新日期：2013-12-01 00:00:00

  • Myelodysplastic patients with raised percentage of hypochromic red cells have evidence of functional iron deficiency.

    abstract：:Raised percentage hypochromic red cells (%HRC) were detected at diagnosis in 10 of 34 consecutive patients with low-risk myelodysplastic syndrome (MDS) [refractory anemia (RA) (4/26) and RA with ring sideroblasts (6/8)], all of whom had normal or increased serum ferritin and bone marrow iron stores. Elevated %HRC has ...

    journal_title：Annals of hematology

    pub_type： 杂志文章

    doi：10.1007/s00277-006-0107-3

    authors： Murphy PT,Quinn JP,O'Donghaile D,Swords R,O'Donnell JR

    更新日期：2006-07-01 00:00:00

  • A phase 1 clinical trial of flavopiridol consolidation in chronic lymphocytic leukemia patients following chemoimmunotherapy.

    abstract：:Patients with chronic lymphocytic leukemia (CLL) who receive chemoimmunotherapy and do not achieve complete remission experience significantly shortened progression-free interval (PFS). Additionally, the majority of patients treated for relapsed disease demonstrate evidence of measurable disease. Eradication of minima...

    journal_title：Annals of hematology

    pub_type： 临床试验,杂志文章

    doi：10.1007/s00277-016-2683-1

    authors： Awan FT,Jones JA,Maddocks K,Poi M,Grever MR,Johnson A,Byrd JC,Andritsos LA

    更新日期：2016-06-01 00:00:00

  • Blood leukocyte subsets and cytokine profile after autologous peripheral blood stem cell transplantation.

    abstract：:High-dose chemotherapy with autologous peripheral blood stem cell transplantation (PBSCT) includes the risk of infectious complications due to neutropenia and therapy-induced immune deviation. In order to understand early immune recovery in this situation, we analyzed the distribution of cell subsets by flow cytometry...

    journal_title：Annals of hematology

    pub_type： 杂志文章

    doi：10.1007/s00277-003-0716-z

    authors： Krause SW,Rothe G,Gnad M,Reichle A,Andreesen R

    更新日期：2003-10-01 00:00:00

  • Hydroxyurea in thalassemia intermedia--a promising therapy.

    abstract：:Pharmacological agents such as hydroxyurea (HU) have been known to cause induction of fetal hemoglobin and possibly may alleviate the symptoms in thalassemia intermedia patients. Thirty-seven patients with beta-thalassemia intermedia were enrolled to assess response to HU therapy. Major response was defined as transfu...

    journal_title：Annals of hematology

    pub_type： 临床试验,杂志文章

    doi：10.1007/s00277-005-1026-4

    authors： Dixit A,Chatterjee TC,Mishra P,Choudhry DR,Mahapatra M,Tyagi S,Kabra M,Saxena R,Choudhry VP

    更新日期：2005-07-01 00:00:00

  • A human Burkitt's lymphoma cell line carrying t(8;22) and t(14;18) translocations.

    abstract：:A combination of chromosomal translocations associated with bcl-2 re-arrangement (t(14;18)) and c-myc re-arrangement (t(8;14), t(8;22), or t(2;8)) is a rare event. We describe the first cell line exhibiting t(14;18) and t(8;22), which will enable us to study the interactions of bcl-2 and c-myc systematically. Cell cul...

    journal_title：Annals of hematology

    pub_type： 杂志文章

    doi：10.1007/s00277-007-0313-7

    authors： Kiefer T,Schüler F,Knopp A,Wimmer M,Hirt C,Schaefer HE,Dölken G

    更新日期：2007-11-01 00:00:00

  • Anti-thymocyte globulin-induced hyperbilirubinemia in patients with myelofibrosis undergoing allogeneic hematopoietic cell transplantation.

    abstract：:Allogeneic hematopoietic cell transplantation (allo-HCT) remains the only curative treatment option for myelofibrosis (MF) despite the emergence of novel targeted therapies. To reduce graft rejection and graft-versus-host disease (GvHD), current allo-HCT protocols often include in vivo T lymphocyte depletion using pol...

    journal_title：Annals of hematology

    pub_type： 杂志文章,多中心研究

    doi：10.1007/s00277-016-2758-z

    authors： Ecsedi M,Schmohl J,Zeiser R,Drexler B,Halter J,Medinger M,Duyster J,Kanz L,Passweg J,Finke J,Bethge W,Lengerke C

    更新日期：2016-10-01 00:00:00

  • Epstein-Barr virus infection in allogeneic marrow grafting: lessons for transplant physicians and virologists.

    abstract：:The relationship between Epstein-Barr virus (EBV) and the host is profoundly disturbed by allogeneic bone marrow transplantation (BMT) because EBV resides in the recipient's hematopoietic system, which has to be destroyed in the majority of cases, and in the donor's hematopoietic system, i.e., the marrow graft. We hav...

    journal_title：Annals of hematology

    pub_type： 杂志文章

    doi：10.1007/BF01715373

    authors： Gratama JW,Oosterveer MA,Lepoutre J,Fibbe WE,Ringdén O,Vossen JM,Willemze R,Bolhuis RL,van Rood JJ,Ernberg I

    更新日期：1992-06-01 00:00:00

  • Low-density lipoprotein cholesterol suppresses apoptosis in human multiple myeloma cells.

    abstract：:Multiple myeloma (MM) is an incurable disease accompanied by low plasma levels of low-density lipoprotein cholesterol (LDL-c). The significance of altered cholesterol metabolism in the pathophysiology of MM remains elusive. Although it has been hypothesized that myeloma cells depend on exogenous cholesterol for its su...

    journal_title：Annals of hematology

    pub_type： 杂志文章

    doi：10.1007/s00277-011-1246-8

    authors： Tirado-Vélez JM,Benítez-Rondán A,Cózar-Castellano I,Medina F,Perdomo G

    更新日期：2012-01-01 00:00:00

  • Comparison of different methods for separation and ex vivo expansion of cord blood progenitor cells.

    abstract：:Umbilical cord blood is capable of hematopoietic stem cell reconstitution in children. However, the major limitation of cord blood is a relatively low content of pluripotent progenitor cells. Thus, safe engraftment for adolescents and for adults is still not predictable and a technology for ex vivo expansion of umbili...

    journal_title：Annals of hematology

    pub_type： 杂志文章

    doi：10.1007/s002770050530

    authors： Schwinger W,Benesch M,Lackner H,Kerbl R,Walcher M,Urban C

    更新日期：1999-08-01 00:00:00

  • In vitro response of blasts to IL-3, GM-CSF, and G-CSF is different for individual AML patients: factors that stimulate leukemic clonogenic cells also enhance Ara-C cytotoxicity.

    abstract：:In vivo, growth factors are currently investigated for their capacity to trigger leukemic stem cells into cycle and thus overcome kinetic drug resistance. In this study, the susceptibility of leukemic clonogenic cells to individual growth factors was related to cytosine-arabinoside (Ara-C) sensitivity. The effects of ...

    journal_title：Annals of hematology

    pub_type： 杂志文章

    doi：10.1007/BF01737421

    authors： Van der Lely N,De Witte T,Wessels J,Raymakers R,Muus P,Preijers F

    更新日期：1994-05-01 00:00:00

  • Mantle cell lymphoma: established therapeutic options and future directions.

    abstract：:During the last few years, new insights into the biology of mantle cell lymphoma have been obtained. However, with a median survival of only 3 years, mantle cell lymphoma remains the lymphoma subtype with the poorest prognosis. At initial diagnosis most patients present with advanced Ann Arbor stage III or IV and conv...

    journal_title：Annals of hematology

    pub_type： 杂志文章,评审

    doi：10.1007/s00277-003-0774-2

    authors： Lenz G,Dreyling M,Hiddemann W

    更新日期：2004-02-01 00:00:00

  • Perinatal management of idiopathic thrombocytopenic purpura in pregnancy: risk factors for passive immune thrombocytopenia.

    abstract：:Thirty-nine pregnant women with idiopathic thrombocytopenic purpura (ITP) were studied in order to evaluate the influence of therapies for maternal ITP on fetal passive immune thrombocytopenia (PIT). Neonatal platelet counts were also compared with platelet counts, amount of PAIgG, and presence of circulating antiplat...

    journal_title：Annals of hematology

    pub_type： 杂志文章

    doi：10.1007/BF01695918

    authors： Yamada H,Fujimoto S

    更新日期：1994-01-01 00:00:00

  • Familial hematological malignancies: new IDH2 mutation.

    abstract：:Isocitrate dehydrogenase IDH 1 and IDH 2 mutations were reported in several cancer forms, especially in hematological malignancies, but were never been investigated in familial aggregation. The aim of this study is to determine whether germline isocitrate dehydrogenase genes mutations are involved.We targeted IDH1 and...

    journal_title：Annals of hematology

    pub_type： 杂志文章

    doi：10.1007/s00277-016-2813-9

    authors： Hamadou WS,Bourdon V,Létard S,Brenet F,Laarif S,Besbes S,Paci A,David M,Penard-Lacronique V,Youssef YB,Laatiri MA,Eisinger F,Mari V,Gesta P,Dreyfus H,Bonadona V,Dugast C,Zattara H,Faivre L,Noguchi T,Khélif A,Sal

    更新日期：2016-12-01 00:00:00

  • Cytogenetic and molecular cytogenetic profile of bone marrow-derived mesenchymal stromal cells in chronic and acute lymphoproliferative disorders.

    abstract：:The possibility that human mesenchymal stromal cells (hMSC) may derive from the malignant clone in hematological malignancies (HM) is a controversial issue. In order to clarify hMSC origin and disclose possible cytogenetic heterogeneity in hMSC belonging to different patients, bone marrow (BM)-derived hMSC samples fro...

    journal_title：Annals of hematology

    pub_type： 杂志文章

    doi：10.1007/s00277-012-1500-8

    authors： Campioni D,Bardi MA,Cavazzini F,Tammiso E,Pezzolo E,Pregnolato E,Volta E,Cuneo A,Lanza F

    更新日期：2012-10-01 00:00:00

  • Cytotoxicity of adriamycin, idarubicin, and vincristine in acute myeloid leukemia: chemosensitization by verapamil in relation to P-glycoprotein expression.

    abstract：:A 4-day colorimetric tetrazolium dye (MTT) assay was used to assess the cytotoxicity of adriamycin (ADM), vincristine (VCR), and idarubicin (IDA) in blasts isolated from 37 patients with newly diagnosed and pretreated acute myeloid leukemia (AML). The effect of verapamil (VRP) as a chemosensitizer was studied in relat...

    journal_title：Annals of hematology

    pub_type： 杂志文章

    doi：10.1007/BF01703946

    authors： Müller MR,Lennartz K,Boogen C,Nowrousian MR,Rajewsky MF,Seeber S

    更新日期：1992-11-01 00:00:00

  • Treatment of primary defective iron-reutilization syndrome: revisited.

    abstract：:We encountered two patients who presented with hypochromic-microcytic anemia and were refractory to iron therapy. The symptoms were suggestive of anemia of chronic disease (ACD); however, there was no evidence of any such disease, either inflammatory or malignant. These patients were reminiscent of patients originally...

    journal_title：Annals of hematology

    pub_type： 杂志文章

    doi：10.1007/s002770000180

    authors： Besa EC,Kim PW,Haurani FI

    更新日期：2000-08-01 00:00:00

  • Phenotype variability of the dominant beta-thalassemia induced in four Dutch families by the rare cd121 (G-->T) mutation.

    abstract：:Eight patients who were carriers of beta-thalassemia induced by the cd121 (G-->T) mutation are described in four nonrelated Dutch families. This mutant, which is considered rare and inherited in a dominant manner, is expressed in a different way among each of the four families and even among carriers of the same famil...

    journal_title：Annals of hematology

    pub_type： 杂志文章

    doi：10.1007/s002770050453

    authors： Giordano PC,Harteveld CL,Michiels JJ,Terpstra W,Schelfhout LJ,Appel IM,Batelaan D,van Delft P,Plug RJ,Bernini LF

    更新日期：1998-12-01 00:00:00

  • Upfront autologous stem cell transplantation for untreated diffuse large B cell lymphoma patients in rituximab era: a systematic review and meta-analysis.

    abstract：:To assess the survival outcomes and adverse events (AEs) of high-intermediate- or high-risk patients with diffuse large B cell lymphoma (DLBCL) who underwent conventional chemotherapy plus rituximab with or without first-line autologous stem cell transplantation (ASCT). Related studies published on Medline, Embase, Co...

    journal_title：Annals of hematology

    pub_type： 杂志文章,meta分析

    doi：10.1007/s00277-020-04016-3

    authors： Ma SY,Tian XP,Cai J,Zhong GZ,Chen X,Huang HQ,Lin TY,Li ZM,Cai QQ

    更新日期：2020-06-01 00:00:00

  • Ruxolitinib treatment for SR-aGVHD in patients with EBV-HLH undergoing allo-HSCT.

    abstract：:Ruxolitinib is a promising option for treating steroid-refractory acute graft-versus-host disease (SR-aGVHD) after allogeneic hematopoietic stem cell transplantation (allo-HSCT). In this study, we describe ruxolitinib treatment for SR-aGVHD in HSCT patients with Epstein-Barr virus-associated hemophagocytic lymphohisti...

    journal_title：Annals of hematology

    pub_type： 杂志文章

    doi：10.1007/s00277-019-03864-y

    authors： Meng G,Wang J,Wang X,Wang Y,Wang Z

    更新日期：2020-02-01 00:00:00

  • Leukemia-propagating cells demonstrate distinctive gene expression profiles compared with other cell fractions from patients with de novo Philadelphia chromosome-positive ALL.

    abstract：:Relapse remains one of the major obstacles in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) even after allogeneic hematopoietic stem cell transplantation. The persistence of leukemia-propagating cells (LPCs) may lead to the recurrence of Ph+ALL. Using a xenograft assay, LPCs enrichment in the ...

    journal_title：Annals of hematology

    pub_type： 杂志文章

    doi：10.1007/s00277-018-3253-5

    authors： Zhao HY,Song Y,Cao XN,Qin YZ,Lai YY,Jiang H,Jiang Q,Huang XJ,Kong Y

    更新日期：2018-05-01 00:00:00

  • Thrombotic thrombocytopenic purpura without any evidence of thrombotic lesions at autopsy.

    abstract：:Diagnosis of thrombotic thrombocytopenic purpura (TTP) is usually based upon the clinical features, and does not always involve histopathological evidence. We recently had experience with a patient who developed the five signs characteristic for TTP. He had been treated for liver cirrhosis associated with chronic hepa...

    journal_title：Annals of hematology

    pub_type： 杂志文章

    doi：10.1007/s002770100323

    authors： Hori A,Kami M,Hamaki T,Yamamoto T,Mori M,Miyakoshi S,Takeuchi K

    更新日期：2001-08-01 00:00:00

  • Long-term outcome after allogeneic bone marrow transplantation for hematological malignancies with non-remission status. Results of a single-center study of 24 patients.

    abstract：:To investigate the problem of allogeneic bone marrow transplantation (allo-BMT) for advanced stage patients, we retrospectively analyzed 24 consecutive patients who underwent allo-BMT in the non-remission stage. Twenty-four patients (19 males and 5 females) with acute leukemia, chronic myelogenous leukemia, and malign...

    journal_title：Annals of hematology

    pub_type： 杂志文章

    doi：10.1007/s00277-002-0506-z

    authors： Tabata M,Satake A,Okura N,Yamazaki Y,Toda A,Nishioka K,Tanaka H,Chin M,Itsukuma T,Yamaguchi M,Misawa M,Kai S,Hara H

    更新日期：2002-10-01 00:00:00

  • Combination of low doses of enzastaurin and lenalidomide has synergistic activity in B-non-Hodgkin lymphoma cell lines.

    abstract：:Less toxic and more active treatments are needed for indolent lymphomas as there is no curative treatment, and patients eventually die due to complications related to their disease. The purpose of the present study was to assess the antitumour activity of the combination of low doses of Enzastaurin and Lenalidomide (R...

    journal_title：Annals of hematology

    pub_type： 杂志文章

    doi：10.1007/s00277-012-1490-6

    authors： Cosenza M,Civallero M,Grisendi G,Marcheselli L,Roat E,Bari A,Sacchi S

    更新日期：2012-10-01 00:00:00

  • Prevalence of increased osmotic fragility of erythrocytes in German blood donors: screening using a modified glycerol lysis test.

    abstract：:We screened for increased osmotic fragility of erythrocytes in 1464 healthy German blood donors. The osmotic fragility was determined by an acidified glycerol lysis test (AGLT) using glycerol-sodium phosphate-buffered NaCl solution. Since the original test described by Zanella et al. [23] showed only low specificity f...

    journal_title：Annals of hematology

    pub_type： 杂志文章

    doi：10.1007/BF01715351

    authors： Eber SW,Pekrun A,Neufeldt A,Schröter W

    更新日期：1992-02-01 00:00:00

  • Overview of 321 patients with idiopathic thrombocytopenic purpura. Retrospective analysis of the clinical features and response to therapy.

    abstract：:In this retrospective study, we evaluated the clinical features and the effects of various treatment modalities on the clinical course in patients diagnosed with idiopathic thrombocytopenic purpura (ITP) at our center between 1984-2000. We retrospectively examined the medical records of 321 (229 females, 92 males) ITP...

    journal_title：Annals of hematology

    pub_type： 杂志文章

    doi：10.1007/s00277-002-0488-x

    authors： Pamuk GE,Pamuk ON,Başlar Z,Ongören S,Soysal T,Ferhanoğlu B,Aydin Y,Ulkü B,Aktuğlu G,Akman N

    更新日期：2002-08-01 00:00:00

  • DNA fragmentation as a consequence of cell cycle traverse in doxorubicin- and idarubicin-treated human lymphoma cells.

    abstract：:We have studied some of the factors involved in the cytotoxic actions of the anticancer anthracycline antibiotics doxorubicin (DOX) and idarubicin (IDA) towards human B-cell lymphoma cells in vitro. IDA was found to accumulate within cells to a greater degree than the related drug DOX for both short (1 h) and long-ter...

    journal_title：Annals of hematology

    pub_type： 杂志文章

    doi：10.1007/BF01757348

    authors： Smith PJ,Rackstraw C,Cotter F

    更新日期：1994-01-01 00:00:00

  • Compound heterozygosity for Hb Korle-Bu (beta(73); Asp-Asn) and Hb E (beta(26); Glu-Lys) with a 3.7-kb deletional alpha-thalassemia in Thai patients.

    abstract：:Hemoglobin (Hb) Korle-Bu (beta73; Asp-Asn) is the most frequent of the rare beta-chain variants in the population of West Africa whereas Hb E (beta26; Glu-Lys) is common among the Southeast Asian population. We report a hitherto undescribed condition in which these two beta-chain variants co-segregate. The proband was...

    journal_title：Annals of hematology

    pub_type： 杂志文章

    doi：10.1007/s00277-002-0485-0

    authors： Changtrakun Y,Fucharoen S,Ayukarn K,Siriratmanawong N,Fucharoen G,Sanchaisuriya K

    更新日期：2002-07-01 00:00:00

  • Mosaicism in Fanconi anemia: concise review and evaluation of published cases with focus on clinical course of blood count normalization.

    abstract：:Fanconi anemia (FA) is a DNA repair disorder resulting from mutations in genes encoding for FA DNA repair complex components and is characterized by variable congenital abnormalities, bone marrow failure (BMF), and high incidences of malignancies. FA mosaicism arises from reversion or other compensatory mutations in h...

    journal_title：Annals of hematology

    pub_type： 杂志文章

    doi：10.1007/s00277-020-03954-2

    authors： Nicoletti E,Rao G,Bueren JA,Río P,Navarro S,Surrallés J,Choi G,Schwartz JD

    更新日期：2020-05-01 00:00:00